PAL-GHK — the lipopeptide that brought GHK-Cu to skincare

GHK is a tripeptide: glycine-histidine-lysine. It was first isolated from human plasma in the early 1970s by Loren Pickart, who found it present in blood and noted its unusual ability to stimulate tissue repair at very low concentrations. Subsequent research identified GHK as a naturally occurring molecule found in plasma, saliva, and urine, and showed that it has high affinity for copper ions — particularly copper(II) — forming the complex known as GHK-Cu. GHK-Cu became the research molecule of interest because copper binding appears to be central to several of GHK's biological effects: it activates copper-dependent enzymes involved in collagen cross-linking and antioxidant defense, upregulates expression of collagen and elastin synthesis genes, and appears to modulate wound healing responses in ways that have been studied in dermatological and cosmetic contexts for several decades.

The problem with putting GHK or GHK-Cu into a skincare product is the same problem facing all cosmetic peptides: the skin doesn't want to let it in. The stratum corneum — the outermost layer of the epidermis, built from flattened, keratin-filled cells embedded in a lipid matrix — exists specifically to keep water in and everything else out. Hydrophilic molecules like peptides face both the physical barrier of the lipid matrix and enzymatic degradation from proteases present in the skin. GHK is small enough (molecular weight around 340 daltons) that some passive penetration is plausible, but "some" is doing real work in that sentence — the amount that crosses the stratum corneum in meaningful concentrations under normal formulation conditions is genuinely uncertain.

PAL-GHK addresses the penetration problem through a pharmaceutical chemistry approach that the cosmetic industry borrowed from drug delivery science. A palmitoyl group — a sixteen-carbon saturated fatty acid chain, the same fatty acid that makes palm oil solid at room temperature — is covalently attached to the N-terminal glycine of the GHK sequence. The result is a lipopeptide: an amphiphilic molecule with a lipid tail that integrates into the lipid matrix of the stratum corneum and a peptide head that carries the biological sequence. The palmitoyl chain serves as a molecular passport — it makes the compound lipophilic enough to partition into and move through the skin's lipid barrier in ways that bare GHK does not.

This is a real and non-trivial chemical modification. The palmitoyl group substantially increases the compound's log P — its partition coefficient, the measure of lipophilicity — making it dramatically more compatible with the stratum corneum's chemistry. Studies using Franz diffusion cell models (an in vitro system used to measure skin penetration) and some in vivo studies have shown that palmitoylated peptides penetrate the stratum corneum more effectively than their unmodified counterparts. The modification works. The question is what happens after the compound crosses the barrier.

Once in the deeper layers of the epidermis and dermis, the hypothesis is that PAL-GHK is cleaved by skin enzymes — peptidases that sever the palmitoyl chain — releasing the free GHK tripeptide to exert its biological effects on fibroblasts and the extracellular matrix. This is a prodrug-like logic: PAL-GHK is the delivery vehicle; GHK is the active payload. The mechanism is coherent and supported by in vitro cell culture data showing that PAL-GHK increases collagen synthesis, improves fibronectin expression, and supports skin matrix remodeling in dermal fibroblast models.

What PAL-GHK does not do is deliver the copper that makes GHK-Cu interesting. The palmitoyl modification replaces the free N-terminus where copper binding occurs, which means PAL-GHK cannot form the copper complex that characterizes the molecule researched more extensively in wound healing and dermatology literature. This is not a trivial distinction. A substantial portion of GHK-Cu's documented biological activity — particularly its effects on copper-dependent enzymes like lysyl oxidase (critical for collagen cross-linking and skin tensile strength) and superoxide dismutase (an antioxidant enzyme) — depends on the copper component. When you buy PAL-GHK in a serum, you are buying the GHK sequence in a better-penetrating delivery vehicle, without the copper. When you buy GHK-Cu, you are buying the copper complex in a form that penetrates less well. These are genuinely different products. Whether the penetration advantage of PAL-GHK outweighs the loss of copper-dependent activity compared to GHK-Cu is a question the cosmetic evidence base can't fully answer.

The cosmetic industry's most commercially successful palmitoylated peptide is Matrixyl — palmitoyl pentapeptide-4, a five-amino-acid peptide with a palmitoyl group, developed by Sederma and appearing in the Olay Regenerist line, among others. Matrixyl has more independent clinical evidence behind it than most cosmetic peptides — there are published split-face randomized controlled trials showing measurable wrinkle depth reductions — which made it a useful anchor for the palmitoylated peptide category and helped establish PAL-GHK and related compounds as credible ingredients by association. The mechanism of Matrixyl is different from PAL-GHK: it mimics a collagen breakdown product, activating fibroblast signaling pathways involved in wound healing and matrix repair. But both are palmitoylated to improve penetration, both are framed around collagen support, and they appear together in many formulations.

The evidence for PAL-GHK specifically is more limited than either Matrixyl or GHK-Cu. Industry-sponsored studies show modest improvements in skin density, elasticity, and fine-line appearance in small cohorts over four to twelve weeks. These are the cosmetic standard — not controlled trials with placebo groups and blinded assessors, but before-and-after studies in selected subjects with favorable lighting, which are sufficient to support regulatory cosmetic claims but insufficient to establish clinical efficacy in any rigorous sense. The effect size, when measured with objective instruments like cutometers (which assess skin elasticity) or silicone replicas (which quantify wrinkle geometry), tends to be modest: improvements in the range of 10 to 20 percent above baseline, which is real but not dramatic.

How cosmetic peptide formulations differ in evidence quality is the important meta-question that PAL-GHK illustrates well. A compound can have a chemically rational mechanism — palmitoylation improves penetration, the released GHK has in vitro effects on fibroblasts — without having robust independent clinical evidence for the specific formulation's real-world effect in skin. The mechanism is upstream of the outcome. Whether the mechanism reliably translates to the outcome, at the concentrations achieved through topical application, in the context of normal photoaged skin rather than controlled lab conditions, is what clinical evidence is supposed to answer — and for most cosmetic peptides, the clinical evidence is thinner than the mechanism story suggests.

PAL-GHK is a reasonable ingredient. It is probably delivering more GHK to the dermis than plain GHK would. What it's delivering is not GHK-Cu, and the copper-dependent effects that make GHK-Cu specifically interesting are not available from this molecule. The skin-penetration problem is real and the palmitoyl approach is a genuine solution to a real problem. Whether the clinical benefit translates into something measurably better than good hydration, sun protection, and a retinoid is the question that compound-sponsored studies are not designed to answer, and that independent research has not yet fully resolved.